Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mylan, Genentech and Roche Reach Agreement on Biosimilar Cancer Drug



The global license will allow Mylan to market its trastuzumab product in multiple countries around the world, excluding Brazil, Mexico and Japan.

Share this!

March 15, 2017 | by Sarah Hand, M.Sc.

Mylan’s biosimilar version of the breast cancer drug, Herceptin, may soon be available, thanks to a settlement reached between the pharmaceutical company and the makers of the reference biologic, Genentech and Roche. The global license will allow Mylan to market its trastuzumab product in multiple countries around the world, excluding Brazil, Mexico and Japan.

A condition of the agreement required Mylan to drop two patent litigation cases against Genentech, regarding Herceptin. Mylan has already submitted an application for the Herceptin biosimilar to the US Food and Drug Administration (FDA), and the company hopes to be the first to introduce the trastuzumab drug to the US market.

“There is an unmet need for access to more affordable versions of biologic products such as trastuzumab,” said Heather Bresch, CEO of Mylan. “We look forward to enhancing access to this important treatment option, which complements our comprehensive cancer care offerings, in the US and around the world.”

Mylan is developing trastuzumab alongside Biocon, along with five other biologic products. While Mylan has sole commercialization rights for the biosimilar in the US, Canada, Japan, Australia, New Zealand and in the European Union, Biocon will work alongside Mylan to commercialize the cancer treatment in the rest of the world.

Mylan is also awaiting European Medicines Agency (EMA) approval for trastuzumab. Currently, the biosimilar is sold in 14 emerging markets around the world.

“With 16 biosimilar products in development,” said Bresch, “we believe Mylan has one of the industry's broadest portfolios of biosimilars and that we will be a leader in bringing high-quality biosimilar products to market given our ability not only to develop and manufacture such complex products, but also to navigate the intricate regulatory and legal environment and successfully commercialize these products on a global basis.”

In 2016, sales of Herceptin reached nearly $4.5 billion in the US and European markets. In addition to its pending regulatory submission for trastuzumab, Mylan and Biocon have also applied for approval for their biosimilar of Amgen’s Neulasta.

Keywords: Biosimilar, Breast Cancer, Biologic


Share this with your colleagues!

German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News

Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News

Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Drug Development During the Last Week


Serialized? Yes. But are Products Still Being Diverted?

Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors

Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model

Imaging-based Subtypes of Pancreatic Cancer

Copyright © 2016-2017 Honeycomb Worldwide Inc.